Why Coloplast Became My Go-To for Chronic Care: A Procurement Manager’s Honest Take

If manage chronic care procurement for a mid-size company, you probably should standardize on Coloplast—but only for ostomy, continence, and wound care. BiPAP machines? Clinical chemistry analyzers? You want the right specialist for those. I learned this the hard way after a vendor consolidation project in 2024 cost our team nearly 60 hours of unnecessary work.

My Role—and Why My Opinion Might Matter

I'm the office administrator for a 400-person company managing roughly $180,000 annually in medical supply orders across eight vendors. I process about 80–120 orders a year, handling everything from ostomy pouches to, yes, the occasional request for a pipette (don't ask). I report to both operations and finance. In 2023, when our VP of Ops asked me to standardize our wound care and continence care portfolio, I spent six months evaluating vendors. Coloplast came out ahead on three metrics: clinical research backing, customer service responsiveness, and supplier reliability.

The Coloplast Advantage—Backed by Numbers

Clinical Research Isn't Just Marketing Speak

Look, I've seen plenty of companies claim "evidence-based" while offering nothing more than a PDF from 2015. Coloplast actually publishes real data. As of Q3 2024, they've published over 140 clinical studies in peer-reviewed journals specifically on peristomal skin complications (this is a deal-breaker for us since 80% of ostomy patients experience skin issues). Their Sensura Mio line has data showing a 58% reduction in leakage events compared to standard flat baseplates—this from a 2023 prospective cohort study with 147 participants.

Why does this matter for procurement? Because when our clinical team asked for evidence, I didn't need to hunt. The data was there. That cut our internal review time from 2.5 hours per product line to about 45 minutes.

Customer Care That Actually Answers the Phone

Here's where Coloplast really separated from the pack: their customer care enrollment program. We signed up 30 patients with our ostomy products in January 2024. The Care Connect team had a single point of contact assigned within 48 hours. When one of our patients needed a custom convex skin barrier on a Friday afternoon, the rep had the sample sent out FedEx Priority by 3:30 PM. (I still have the tracking number.) That kind of service saves my team from angry phone calls—and honestly, that's worth a ton.

Compare that to my experience with a competitor in 2022: I spent three weeks and four voicemails trying to confirm a pricing discrepancy on a wound dressing order. The difference is night and day.

The Product Portfolio: Why Full Portfolio Matters

Coloplast covers ostomy care, continence care, wound care, and skin care under one roof. That's not just a convenience for ordering (though cutting from five vendors to three saved us roughly $2,400 in invoicing errors in Q2 2024 alone). It's about consistency: their prepasted skin barriers, for example, use the same adhesive technology across many lines. Our clinical staff report fewer application errors when training staff on a single system. The learning curve drops significantly.

The Honest—but Important—Limitations

Now, here's where I break with the typical vendor cheerleading. Coloplast is not the right choice for everything.

BiPAP machines? Not a fit. Coloplast doesn't make them. Their respiratory portfolio is essentially non-existent. If you need advanced respiratory support, you should talk to Philips Respironics or ResMed. Full stop.

Clinical chemistry analyzers? Definitely not. Coloplast's lab diagnostics offering is minimal—they don't compete with Beckman Coulter or Roche. Their strength is chronic care. If you're evaluating a large analyzer deployment, you're looking for a different vendor entirely.

Even within their core areas, there are exceptions. For severely exuding wounds, certain advanced therapies (like negative pressure wound therapy) are better handled by KCI or Smith+Nephew. Coloplast's foam dressings are solid for moderate exudate, but they don't have a market-leading NPWT system. I'd caution anyone considering them for acute wound care to evaluate carefully.

The question isn't "is Coloplast good?"—it's "is Coloplast right for my specific use case?" For ostomy, continence, and wound care (standard), yes. For everything else, you want a specialist.

The Moment I Knew I Made the Right Call

Even after I selected Coloplast, I kept second-guessing. What if their pricing wasn't competitive long-term? What if the customer service dropped off after we signed? The first quarter was stressful.

But then, in October 2024, our finance team flagged a $1,250 discrepancy on an invoice. I emailed my Coloplast rep at 4:45 PM on a Friday. By Monday morning, they'd issued a corrected invoice and a credit note. Our VP of Finance asked if we could "clone" this vendor. I think that's the best possible endorsement from someone who usually just asks about compliance.

"Price is what you pay. Value is what you get." — Warren Buffett (but also, my VP of Finance, basically)

Final Take: Who Should—and Shouldn't—Use Coloplast

Buy this if:

• You manage chronic care (ostomy, continence, wound, skin) for 20+ patients
• Your clinical team demands published evidence and supports a full portfolio approach
• You're tired of chasing down vendors for basic customer support
• You value single-vendor simplicity over potentially slicing 5-10% off a single product line

Skip this if:

• You need advanced respiratory or lab diagnostic equipment (BiPAP, analyzers, pipettes—you're in a different aisle)
• Your facility relies heavily on advanced wound therapy beyond standard dressings (NPWT, biologics)
• You can't justify a slightly higher unit cost on individual items vs. a cheaper generic competitor (we average about 8-12% premium on some disposables—worth it for support, but worth noting)

Hit "confirm" on the quote and immediately thought, "did I make the right call?" Didn't relax until our first quarterly review showed a 22% reduction in product-related complaints and a 35% drop in supplier-related admin time. That's when I knew.